Literature DB >> 2156900

Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice.

M J Cannon1, P Pisa, R I Fox, N R Cooper.   

Abstract

C.B-17 scid mice were reconstituted by intraperitoneal injection of human tonsil cells or PBL from EBV-seronegative donors. Subsequent injection of EBV resulted in the rapid development (within 19-33 d) of aggressive, fatal, lymphoproliferative disorders of human B cell origin. Autopsies revealed solid tumors in the abdomen, and occasionally in the liver, thymus, or spleen. Histopathologic analysis showed that the tumors were high-grade immunoblastic lymphomas and FACS analyses of tumor cells indicated that they were of human B-lymphoid origin. The tumor cells grew in vitro and induced new tumors on injection into severe combined immunodeficient (SCID) mice. Karyotypic analysis and Southern blots for c-myc or bcl-2 rearrangements revealed no chromosomal abnormalities and translocations. Southern blot analysis also showed that the cells possessed EBV DNA sequences. Although these tumors undoubtedly reflect infection of the transferred B cells with EBV in vivo, intraperitoneal transfer of short-term lymphoid cell lines transformed in vitro with EBV resulted in ascites production without evidence of tumor formation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156900      PMCID: PMC296572          DOI: 10.1172/JCI114573

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Identification of EBV-DNA in tumour cells of AIDS-related lymphomas by in-situ hybridisation.

Authors:  S J Hamilton-Dutoit; G Pallesen; J Karkov; P Skinhøj; M B Franzmann; C Pedersen
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

2.  Epstein-Barr-virus-specific T-cell memory in renal-allograft recipients under long-term immunosuppression.

Authors:  J S Gaston; A B Rickinson; M A Epstein
Journal:  Lancet       Date:  1982-04-24       Impact factor: 79.321

3.  Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping.

Authors:  T Dambaugh; C Beisel; M Hummel; W King; S Fennewald; A Cheung; M Heller; N Raab-Traub; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

4.  Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones.

Authors:  M L Cleary; M A Epstein; S Finerty; R F Dorfman; G W Bornkamm; J K Kirkwood; A J Morgan; J Sklar
Journal:  Science       Date:  1985-05-10       Impact factor: 47.728

5.  T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A.

Authors:  A B Rickinson; M Rowe; I J Hart; Q Y Yao; L E Henderson; H Rabin; M A Epstein
Journal:  Cell Immunol       Date:  1984-09       Impact factor: 4.868

6.  Epstein-Barr virus (EBV)-induced lymphoproliferative disease in cotton-topped marmosets.

Authors:  D R Johnson; L G Wolfe; G Levan; G Klein; I Ernberg; P Aman
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

7.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

8.  Monoclonality of lymphoproliferative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements.

Authors:  M L Cleary; R Warnke; J Sklar
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

9.  Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy.

Authors:  D W Hanto; K J Gajl-Peczalska; G Frizzera; D C Arthur; H H Balfour; K McClain; R L Simmons; J S Najarian
Journal:  Ann Surg       Date:  1983-09       Impact factor: 12.969

10.  Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients.

Authors:  G Frizzera; D W Hanto; K J Gajl-Peczalska; J Rosai; R W McKenna; R K Sibley; K P Holahan; L L Lindquist
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

View more
  40 in total

Review 1.  Are natural killer cells the key to treating Epstein-Barr virus-associated lymphoproliferative disorders?

Authors:  M J Robertson
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 3.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

4.  Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.

Authors:  J Avila-Cariño; S Torsteinsdottir; B Ehlin-Henriksson; M G Masucci; E Klein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.

Authors:  M D Moore; M J Cannon; A Sewall; M Finlayson; M Okimoto; G R Nemerow
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Hemagglutination and graft-versus-host disease in the severe combined immunodeficiency mouse lymphoproliferative disease model.

Authors:  S J Pirruccello; H Nakamine; K W Beisel; K L Kleveland; M Okano; Y Taguchi; J R Davis; M L Mahloch; D T Purtilo
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

Review 7.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

8.  Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro.

Authors:  J I Cohen; G R Picchio; D E Mosier
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease.

Authors:  M A Duchosal; S A Eming; P J McConahey; F J Dixon
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

10.  Morphologic and immunophenotypic characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease.

Authors:  P S Randhawa; A Zeevi; C Alvares; S Gollin; R Agostini; E Yunis; S Saidman; L Contis; A J Demetris; M A Nalesnik
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-06       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.